Musk accuses Twitter of ‘resisting and thwarting’ his right to information on fake accounts

Musk accuses Twitter of ‘resisting and thwarting’ his right to information on fake accounts


Musk’s plan to buy Twitter has worried policymakers around the world.

Joe Skipper | Reuters

Elon Musk accused Twitter of “resisting and thwarting” his right to information about fake accounts on the platform, calling it a “clear material breach” of the terms of their merger agreement in a letter to the company on Monday.

“Mr. Musk reserves all rights resulting therefrom, including his right not to consummate the transaction and his right to terminate the merger agreement,” the letter, signed by Skadden attorney Mike Ringler, says.

Twitter shares were down 5% Monday morning.

Musk wrote on Twitter last month that his $44 billion purchase of the company would not move forward until he had more information about the number of fake accounts on the service. Some analysts interpreted the move as a negotiation tactic for a lower price.

He said his team would do a random sampling to calculate the number of fake accounts, but Twitter’s CEO later explained that nonpublic information would be necessary to get an accurate count. Twitter executives told staff there’s “no such thing” as putting the deal on hold as Musk claimed, according to a report in Bloomberg.

In Monday’s letter, Musk’s lawyer wrote that the merger agreement requires Twitter to provide the data Musk requested and disputed the company’s alleged claim that it is only required to provide information for the limited purpose of helping to close the transaction.

“To the contrary, Mr. Musk is entitled to seek, and Twitter is obligated to provide, information and data for, inter alia, ‘any reasonable business purpose related to the consummation of the transaction,'” the letter says.

“At this point, Mr. Musk believes Twitter is transparently refusing to comply with its obligations under the merger agreement, which is causing further suspicion that the company is withholding the requested data due to concern for what Mr. Musk’s own analysis of that data will uncover,” it continues.

According to the letter, Musk would agree to ensure anyone reviewing the data would be bound by a non-disclosure agreement and he would not use any “competitively sensitive information” if the deal doesn’t close.

Twitter did not immediately respond to a request for comment.

Subscribe to CNBC on YouTube.

WATCH: A timeline of the Elon Musk-Twitter takeover saga



Source

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’
World

Howard Marks says there are very few cheap stocks: ‘Bargains come when people panic’

Howard Marks warned that investors hunting for bargains may be disappointed, saying markets are still far from distressed levels despite bouts of volatility. The co-founder and co-chairman of Oaktree Capital Management, who famously foresaw the dot-com bubble, said the current environment reflects an ongoing “tug of war” between bullish and bearish forces, with optimism largely […]

Read More
Investors are misreading news about the Iran war, analysts say as markets whipsaw
World

Investors are misreading news about the Iran war, analysts say as markets whipsaw

An Iranian flag flutters as a woman walks past damaged buildings amid a 10-day ceasefire between Lebanon and Israel, in the southern suburbs of Beirut, Lebanon, April 20, 2026. Marko Djurica | Reuters “Complacent” investors risk getting wrong-footed as they continue to misread developments in the Iran war, analysts said after markets reacted to the […]

Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to  billion
World

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]

Read More